Chicago Equity Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Chicago Equity Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$810K	Sell	2,310 -100	-4%	-$36.8K	0.08%	321
2019 Q4	$892K	Sell	2,410 -1,300	-35%	-$458K	0.05%	484
2019 Q3	$1.23M	Sell	3,710 -50	-1%	-$16.3K	0.06%	435
2019 Q2	$1.18M	Buy	3,760 +1,660	+79%	+$497K	0.05%	483
2019 Q1	$642K	Buy	2,100 +510	+32%	+$138K	0.02%	617
2018 Q4	$369K	Buy	+1,590	New	+$427K	0.01%	685
2018 Q3	–	Sell	-4,150	Closed	-$1.2M	–	802
2018 Q2	$1.2M	Buy	4,150 +275	+7%	+$75.9K	0.04%	490
2018 Q1	$969K	Hold	3,875	–	–	0.03%	510
2017 Q4	$925K	Buy	3,875 +2,020	+109%	+$489K	0.03%	516
2017 Q3	$412K	Sell	1,855 -2,845	-61%	-$640K	0.01%	647
2017 Q2	$1.06M	Buy	+4,700	New	+$1.02M	0.03%	498
2016 Q1	–	Sell	-13,305	Closed	-$1.84M	–	587
2015 Q4	$1.84M	Sell	13,305 -6,385	-32%	-$885K	0.05%	267
2015 Q3	$2.65M	Buy	19,690 +195	+1%	+$28.1K	0.07%	220
2015 Q2	$2.94M	Buy	+19,495	New	+$2.79M	0.08%	177

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Chicago Equity Partners's BIO Position: Q1 2020 in Review

Chicago Equity Partners reduced its Bio-Rad Laboratories Class A (BIO) stake by 4.1% in Q1 2020, selling an estimated $36.8K and leaving 2,310 shares worth $810K. The position accounts for 0.08% of the portfolio, ranked #321.

Chicago Equity Partners first reported a position in BIO in Q2 2015 and has held it in 14 quarters since. The position peaked at $2.94M in Q2 2015. 406 funds tracked by Wall St. Rank hold BIO as of Q1 2020.

Chicago Equity Partners held 2,310 shares of Bio-Rad Laboratories Class A worth $810K as of Q1 2020.
Chicago Equity Partners sold 100 Bio-Rad Laboratories Class A shares in Q1 2020, an estimated $36.8K.
Bio-Rad Laboratories Class A made up 0.08% of Chicago Equity Partners's portfolio in Q1 2020, its #321 holding.
Chicago Equity Partners first reported a position in Bio-Rad Laboratories Class A in Q2 2015 and has held it in 14 quarters since.
Chicago Equity Partners's Bio-Rad Laboratories Class A position peaked at $2.94M in Q2 2015.
406 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.